Prognosis and clinical evolution of new and current genetic and proteic biomarkers in lung cancer

• Grant number: 13/14277-4
• Support Opportunities: Regular Research Grants
• Start date: August 01, 2014
• End date: July 31, 2016
• Field of knowledge: Health Sciences - Medicine - Pathological Anatomy and Clinical Pathology
• Principal Investigator: Vera Luiza Capelozzi
• Grantee: Vera Luiza Capelozzi
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Lung cancer remains the main cause of cancer deaths in the Brazilian population. Even suspecting that the numbers are under-estimated, this neoplasia occupies a place among the most prevalent. In the last decades, several changes have occurred in diagnosis and treatment of this disease. Better therapeutic results and preventive strategies depend on the constant increase on the knowledge of the epidemiological and biological characteristics of lung cancer patients in different populations. Thus, the main goal of the present project is to identify the actual scenario of lung câncer in patients from three terciary hospitals in Brazil. With the expansion of the available technology to the SUS patients, this project will turn into reality news tools that, in the future, might be applied in different medical centers in Brazil, which study and treat this disease. Through our management, the following aims will be achieved: Describe the disease in Brazil contributing to prevalence and survival data information in different geographic regions and social economic groups; Contribute to the clinic, epidemiologic and molecular profile knowledge of lung câncer in Brazil; Establish a number of informations that could be transmited to other national institutionsthat work in the fight against Lung Cancer in the future, contributing to the development of new cooperative studies; Facilitate the access to molecular diagnosis to SUS patients, a very important tool in the survival data and efficacy of treatment evaluation;üStrength the health politics planning in terms of primary, secondary and terciary prevention allowing the evaluation of cost-effectiveness for technology incorporation decisions. (AU)

Scientific publications

(7)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

CHRISTMANN, ROMY B.; WOOTEN, ALICIA; SAMPAIO-BARROS, PERCIVAL; BORGES, CLAUDIA L.; CARVALHO, CARLOS R. R.; KAIRALLA, RONALDO A.; FEGHALI-BOSTWICK, CAROL; ZIEMEK, JESSICA; MEI, YU; GOUMMIH, SALMA; et al. miR-155 in the progression of lung fibrosis in systemic sclerosis. ARTHRITIS RESEARCH & THERAPY, v. 18, JUL 5 2016. (13/14277-4)

ANTONANGELO, LEILA; TUMA, TAILA; FABRO, ALEXANDRE; ACENCIO, MILENA; TERRA, RICARDO; PARRA, EDWIN; VARGAS, FRANCISCO; TAKAGAKI, TERESA; CAPELOZZI, VERA. Id-1, Id-2, and Id-3co-expression correlates with prognosis in stage I and II lung adenocarcinoma patients treated with surgery and adjuvant chemotherapy. Experimental Biology and Medicine, v. 241, n. 11, p. 1159-1168, JUN 2016. (13/14277-4, 11/52095-0)

PARRA, EDWIN ROGER; JIANG, MEI; MACHADO-RUGOLO, JULIANA; YAEGASHI, LYGIA BERTALHA; PRIETO, TABATHA; FARHAT, CECILIA; DE SA, VANESSA KAREN; NAGAI, MARIA APARECIDA; CORDEIRO DE LIMA, VLADMIR CLAUDIO; TAKAGAKI, TEREZA; et al. Variants in Epithelial-Mesenchymal Transition and Immune Checkpoint Genes Are Associated With Immune Cell Profiles and Predict Survival in Non-Small Cell Lung Cancer. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, v. 144, n. 10, p. 11-pg., 2020-10-01. (13/14277-4)

FELIX, RENATO GONCALVES; CARVALHO BOVOLATO, ANA LIVIA; COTRIM, ONDINA SILVIA; LEAO, PATRICIA DOS SANTOS; BATAH, SABRINA SETEMBRE; GOLIM, MARJORIE DE ASSIS; VELOSA, ANA PAULA; TEODORO, WALCY; MARTINS, VANESSA; CRUZ, FERNANDA FERREIRA; et al. Adipose-derived stem cells and adipose-derived stem cell-conditioned medium modulate in situ imbalance between collagen I-and collagen V-mediated IL-17 immune response recovering bleomycin pulmonary fibrosis. HISTOLOGY AND HISTOPATHOLOGY, v. 35, n. 3, p. 289-301, MAR 2020. (11/09181-2, 18/20403-6, 13/14277-4, 12/03543-2, 12/07040-5)

MACHADO-RUGOLO, JULIANA; PRIETO, TABATHA GUTIERREZ; FABRO, ALEXANDRE TODOROVIC; PARRA CUENTAS, EDWIN ROGER; SA, VANESSA KAREN; BALDAVIRA, CAMILA MACHADO; RAINHO, CLAUDIA APARECIDA; CASTELLI, ERICK C.; FARHAT, CECILIA; TAKAGAKI, TERESA YAE; et al. Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort. PHARMACOGENOMICS & PERSONALIZED MEDICINE, v. 14, p. 239-252, 2021. (18/20403-6, 13/14277-4)

DE VILHENA, ALYNE FONSECA; DAS NEVES PEREIRA, JOAO CARLOS; PARRA, EDWIN ROGER; BALANCIN, MARCELO LUIZ; AB'SABER, ALEXANDRE; MARTINS, VANESSA; FARHAT, CECILIA; ABRANTES, MARCELO MILITAO; MILANEZ DE CAMPOS, JOSE RIBAS; TEDDE, MIGUEL LIA; et al. Histomorphometric evaluation of the Ki-67 proliferation rate and CD34 microvascular and D2-40 lymphovascular densities drives the pulmonary typical carcinoid outcome. HUMAN PATHOLOGY, v. 81, p. 201-210, NOV 2018. (13/14277-4)

MACHADO-RUGOLO, JULIANA; FABRO, ALEXANDRE TODOROVIC; ASCHERI, DANIEL; FARHAT, CECILIA; AB'SABER, ALEXANDRE MUXFELDT; DE SA, VANESSA KAREN; NAGAI, MARIA APARECIDA; TAKAGAKI, TERESA; TERRA, RICARDO; PARRA, EDWIN ROGER; et al. Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non-small cell lung cancer. HUMAN PATHOLOGY, v. 83, p. 177-191, JAN 2019. (13/14277-4)